mcstroth's profile picture. urologic oncologist @OHSUurology he/him

Marshall Strother

@mcstroth

urologic oncologist @OHSUurology he/him

Pinned

I hereby submit my twitter petition for all journal article pdfs to automatically include the supplementary materials at the end. Extra clicks + pain of organizing extra PDFs >>> a few extra wasted KB of hard drive space @JUrology


Marshall Strother reposted

📢 New publication in European Urology We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized…

EUplatinum's tweet image. 📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized…

Marshall Strother reposted

doi.org/10.1016/j.euru… Final THOR-2 analysis: Oral erdafitinib significantly improved RFS vs intravesical chemotherapy and produced durable CRs in FGFR-altered HR & IR #NMIBC—bringing precision oncology into NMIBC care. @JimCatto @nikhilvasdevuro @PignotG @BladderCancerUS


Marshall Strother reposted

During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone. @OncoAlert @kidneycan

DrChoueiri's tweet image. During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone. 

@OncoAlert @kidneycan…
DrChoueiri's tweet image. During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone. 

@OncoAlert @kidneycan…
DrChoueiri's tweet image. During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone. 

@OncoAlert @kidneycan…

Marshall Strother reposted

Results from the phase II TOMBOLA published in @Annals_Oncology ctDNA+ patients treated early with atezolizumab (60% CR) and ctDNA– patients safely spared adjuvant therapy (97% 1-year RFS). @OncoAlert @LDyrskjot @urotoday annalsofoncology.org/article/S0923-…

scocmem's tweet image. Results from the phase II TOMBOLA published in @Annals_Oncology 

ctDNA+ patients treated early with atezolizumab (60% CR) and ctDNA– patients safely spared adjuvant therapy (97% 1-year RFS). 

@OncoAlert @LDyrskjot @urotoday

annalsofoncology.org/article/S0923-…
scocmem's tweet image. Results from the phase II TOMBOLA published in @Annals_Oncology 

ctDNA+ patients treated early with atezolizumab (60% CR) and ctDNA– patients safely spared adjuvant therapy (97% 1-year RFS). 

@OncoAlert @LDyrskjot @urotoday

annalsofoncology.org/article/S0923-…
scocmem's tweet image. Results from the phase II TOMBOLA published in @Annals_Oncology 

ctDNA+ patients treated early with atezolizumab (60% CR) and ctDNA– patients safely spared adjuvant therapy (97% 1-year RFS). 

@OncoAlert @LDyrskjot @urotoday

annalsofoncology.org/article/S0923-…

Marshall Strother reposted

Do we need to routinely image the pelvis in surveillance of Stage I testicular cancer? Multi-institutional retrospective study showing 1.3% pts with no prior cryptorchidism or inguinal/scrotal surgery had pelvis only recurrence. @HamedA3112 @UMNUrology @uroegg @RHamiltonUrol


Marshall Strother reposted

Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women—a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU) - Clinical Microbiology and Infection clinicalmicrobiologyandinfection.org/article/S1198-…


Marshall Strother reposted

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1

DrChoueiri's tweet image. IT IS THIS TIME OF THE YEAR AGAIN!

            TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1…
DrChoueiri's tweet image. IT IS THIS TIME OF THE YEAR AGAIN!

            TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1…

Marshall Strother reposted

Fascinatingly counterintuitive If observation is indeed true, many potential explanations (P.S. article in same issue shows surgeon mortality is higher than non-surgeon physicians) Association Between Surgeon Stress and Major Surgical Complications jamanetwork.com/journals/jamas…


Marshall Strother reposted

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer pfizer.com/news/press-rel…

tompowles1's tweet image. Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer  pfizer.com/news/press-rel…

Marshall Strother reposted

Big positive step for metastatic prostate cancer. Precision oncology in mCSPC should be global standard of care as it aids treatment sequencing. AMPLITUDE demonstrates a convincing PFS benefit for BRCA2 population without compromising QOL.

🎯🎯 FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC | OncLive 🙌🙌 ⁦@OncoAlert⁩ ⁦@GuardConsortium⁩ ⁦@myESMO⁩ ⁦@ASCOonclive.com/view/fda-appro…



Marshall Strother reposted

Always used hemostatic agents for PNx, then used for 50% of cases during the trial, now will only use very selectively.....lots of gratitude to the team and patients who made this happen auajournals.org/doi/10.1097/JU…


Marshall Strother reposted

#TrialsinProgress - TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized phase III clinical trial of docetaxel with androgen receptor pathway inhibitors for #mCSPC patients with a suboptimal PSA response. Presentation by @sokolova_md @OHSUNews. #SUO25 written coverage by @zklaassen_md

urotoday's tweet image. #TrialsinProgress - TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized phase III clinical trial of docetaxel with androgen receptor pathway inhibitors for #mCSPC patients with a suboptimal PSA response. Presentation by @sokolova_md @OHSUNews. #SUO25 written coverage by @zklaassen_md…

Marshall Strother reposted

@IanMetzler Highlighting the role of diminished nephrogram in evaluating renal obstruction @OHSUurology 🪨 diminished nephrogram is another tool to tell us if the kidney is truly obstructed! 🪨 this can be used as a tool when hydronephrosis cannot be relied upon

BogdanaSchmidt's tweet image. @IanMetzler Highlighting the role of diminished nephrogram in evaluating renal obstruction  @OHSUurology 
🪨 diminished nephrogram is another tool to tell us if the kidney is truly obstructed! 
🪨 this can be used as a tool when hydronephrosis cannot be relied upon
BogdanaSchmidt's tweet image. @IanMetzler Highlighting the role of diminished nephrogram in evaluating renal obstruction  @OHSUurology 
🪨 diminished nephrogram is another tool to tell us if the kidney is truly obstructed! 
🪨 this can be used as a tool when hydronephrosis cannot be relied upon

Marshall Strother reposted

Exciting 23 year update from the ERSPC #prostatecancer screening trial from @MoniqueRoobol and team, and a great editorial @VickersBiostats. NND is down to 12 and still falling! And the benefit:harm ratio would be even better w/ modern screening/dx/tx pathways.

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7 Editorial: Early Detection of Prostate Cancer —…

NEJM's tweet image. At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7 

Editorial: Early Detection of Prostate Cancer —…


Marshall Strother reposted

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

ERPlimackMD's tweet image. The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
ERPlimackMD's tweet image. The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
ERPlimackMD's tweet image. The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
ERPlimackMD's tweet image. The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

Marshall Strother reposted

A historic moment at #ESMO25. Dr Christof Vulsteke presents #KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC: ✅ EFS HR 0.40 ✅OS HR 0.50 ✅pCR 57% vs 9% Four rounds of applause from a packed room 👏 @OncoAlert @myESMO @Uromigos @urotoday

scocmem's tweet image. A historic moment at #ESMO25. Dr Christof Vulsteke presents 
#KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC:
✅ EFS HR 0.40
✅OS HR 0.50
✅pCR 57% vs 9%
Four rounds of applause from a packed room 👏

@OncoAlert @myESMO @Uromigos @urotoday
scocmem's tweet image. A historic moment at #ESMO25. Dr Christof Vulsteke presents 
#KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC:
✅ EFS HR 0.40
✅OS HR 0.50
✅pCR 57% vs 9%
Four rounds of applause from a packed room 👏

@OncoAlert @myESMO @Uromigos @urotoday
scocmem's tweet image. A historic moment at #ESMO25. Dr Christof Vulsteke presents 
#KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC:
✅ EFS HR 0.40
✅OS HR 0.50
✅pCR 57% vs 9%
Four rounds of applause from a packed room 👏

@OncoAlert @myESMO @Uromigos @urotoday

Marshall Strother reposted

5-yr efficacy & ctDNA results from CheckMate 274: Adjv Nivo vs PBO for HR MIUC #ESMO25 @urotoday 🌐 ⬆️DFS: all pts (HR 0.74, 95% CI 0.61-0.90) and PD-L1 ≥ 1% (HR 0.58, 95% CI 0.42-0.79) 🌐⬆️DFS: MIBC pts (HR 0.66, 95% CI 0.53-0.81) and PD-L1 ≥ 1% (HR 0.50, 95% CI 0.36-0.72)…

zklaassen_md's tweet image. 5-yr efficacy & ctDNA results from CheckMate 274: 
Adjv Nivo vs PBO for HR MIUC #ESMO25 @urotoday 

🌐 ⬆️DFS: all pts (HR 0.74, 95% CI 0.61-0.90) and PD-L1 ≥ 1% (HR 0.58, 95% CI 0.42-0.79)
🌐⬆️DFS: MIBC pts (HR 0.66, 95% CI 0.53-0.81) and PD-L1 ≥ 1% (HR 0.50, 95% CI 0.36-0.72)…
zklaassen_md's tweet image. 5-yr efficacy & ctDNA results from CheckMate 274: 
Adjv Nivo vs PBO for HR MIUC #ESMO25 @urotoday 

🌐 ⬆️DFS: all pts (HR 0.74, 95% CI 0.61-0.90) and PD-L1 ≥ 1% (HR 0.58, 95% CI 0.42-0.79)
🌐⬆️DFS: MIBC pts (HR 0.66, 95% CI 0.53-0.81) and PD-L1 ≥ 1% (HR 0.50, 95% CI 0.36-0.72)…
zklaassen_md's tweet image. 5-yr efficacy & ctDNA results from CheckMate 274: 
Adjv Nivo vs PBO for HR MIUC #ESMO25 @urotoday 

🌐 ⬆️DFS: all pts (HR 0.74, 95% CI 0.61-0.90) and PD-L1 ≥ 1% (HR 0.58, 95% CI 0.42-0.79)
🌐⬆️DFS: MIBC pts (HR 0.66, 95% CI 0.53-0.81) and PD-L1 ≥ 1% (HR 0.50, 95% CI 0.36-0.72)…
zklaassen_md's tweet image. 5-yr efficacy & ctDNA results from CheckMate 274: 
Adjv Nivo vs PBO for HR MIUC #ESMO25 @urotoday 

🌐 ⬆️DFS: all pts (HR 0.74, 95% CI 0.61-0.90) and PD-L1 ≥ 1% (HR 0.58, 95% CI 0.42-0.79)
🌐⬆️DFS: MIBC pts (HR 0.66, 95% CI 0.53-0.81) and PD-L1 ≥ 1% (HR 0.50, 95% CI 0.36-0.72)…

Marshall Strother reposted

ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity @JoshMeeks

tompowles1's tweet image. ALBAN, POTOMAC & CREST  #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity  @JoshMeeks

Marshall Strother reposted

How fast do #rcc tumor thrombi grow? 📈 In our cohort @MayoUrology (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.

vidit_sharma_'s tweet image. How fast do #rcc  tumor thrombi grow? 📈 In our cohort @MayoUrology  (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.
vidit_sharma_'s tweet image. How fast do #rcc  tumor thrombi grow? 📈 In our cohort @MayoUrology  (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.
vidit_sharma_'s tweet image. How fast do #rcc  tumor thrombi grow? 📈 In our cohort @MayoUrology  (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.
vidit_sharma_'s tweet image. How fast do #rcc  tumor thrombi grow? 📈 In our cohort @MayoUrology  (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.

Loading...

Something went wrong.


Something went wrong.